Abstract
In this issue of Urology, Wymer et al report on the cost effectiveness of different surgical treatment strategies for benign prostatic hyperplasia (BPH) as measured by Medicare cost, quality-adjusted life years, and incremental cost-effective ratios at 5 years after surgery. Specifically, they compared holmium laser enucleation of the prostate (HoLEP), bipolar transurethral resection of the prostate (B-TURP), water vapor thermal therapy (WVTT), and prostatic urethral lift (PUL) for prostates under 80 g and HoLEP versus simple prostatectomy (SP) for glands larger than 80 grams.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
